Stock Yearly Return 2021
Start date: 01/04/2021
End date: 12/31/2021
Start price/share: $6.36
End price/share: $3.21
Dividends collected/share: $0.00
Total return: -49.53%
MNPR Average Annual Return: -50.08%
Starting investment: $10,000.00
Ending investment: $5,047.00
Years: 0.99


MNPR average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare MNPR average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into MNPR


Also see:
MNPR YTD return
MNPR average annual return 10 years
Monopar Therapeutics is a biopharmaceutical company focused on developing therapeutics for cancer patients. Co. has compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a mucoadhesive buccal anti-inflammatory tablet for the prevention and treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (5-imino-13-deoxydoxorubicin), a clinical stage topoisomerase II-alpha targeted analog of doxorubicin to retain anticancer activity; and MNPR-101, a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor for the treatment of solid cancers. The MNPR stock yearly return is shown above.

The yearly return on the MNPR stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2021 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the MNPR annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree MNPR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Monopar Therapeutics (MNPR) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

MODV Average Annual Return
MOH Average Annual Return
MORF Average Annual Return
MOTS Average Annual Return
MOVE Average Annual Return
MRK Average Annual Return
MRKR Average Annual Return
MRNA Average Annual Return
MRNS Average Annual Return
MRSN Average Annual Return
More Healthcare companies »

 

MNPR Stock Yearly Return 2021 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.